Maplight Therapeutics (NASDAQ:MPLT) Upgraded to “Hold” at Wall Street Zen

Maplight Therapeutics (NASDAQ:MPLT) was upgraded by stock analysts at Wall Street Zen to a “hold” rating in a research note issued to investors on Wednesday.

Maplight Therapeutics Trading Down 4.0%

Shares of Maplight Therapeutics stock traded down $0.67 on Wednesday, reaching $16.24. 242,178 shares of the company were exchanged.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients.